Tags

Type your tag names separated by a space and hit enter

CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
J Neurochem. 2013 Dec; 127(5):681-90.JN

Abstract

The overlapping clinical features of Alzheimer's disease (AD) and Dementia with Lewy bodies (DLB) make differentiation difficult in the clinical environment. Evaluating the CSF levels of biomarkers in AD and DLB patients could facilitate clinical diagnosis. CSF Visinin-like protein-1 (VILIP-1), a calcium-mediated neuronal injury biomarker, has been described as a novel biomarker for AD. The aim of this study was to investigate the diagnostic utility of CSF VILIP-1 and VILIP-1/Aβ1-42 ratio to distinguish AD from DLB. Levels of CSF VILIP-1, t-tau, p-tau181P , Aβ1-42 , and α-synuclein were measured in 61 AD patients, 32 DLB patients, and 40 normal controls using commercial ELISA kits. The results showed that the CSF VILIP-1 level had significantly increased in AD patients compared with both normal controls and DLB patients. The CSF VILIP-1 and VILIP-1/Aβ1-42 levels had enough diagnostic accuracy to allow the detection and differential diagnosis of AD. Additionally, CSF VILIP-1 levels were positively correlated with t-tau and p-tau181P within each group and with α-synuclein in the AD and control groups. We conclude that CSF VILIP-1 could be a diagnostic marker for AD, differentiating it from DLB. The analysis of biomarkers, representing different neuropathologies, is an important approach reflecting the heterogeneous features of AD and DLB. Neuronal Ca(2+) -sensor protein VILIP-1 has been implicated in the calcium-mediated neuronal injury and pathological change of AD. The CSF VILIP-1 and VILIP-1/Aβ1-42 levels had enough diagnostic accuracy to allow the detection and differential diagnosis of AD. CSF VILIP-1 is a useful biomarker for AD. Evaluating the CSF levels of VILIP-1 in AD and DLB patients could facilitate clinical diagnosis.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Luo X
Department of Neurology, Guangzhou Brain Hospital, Affiliated Hospital of Guangzhou Medical College, Guangzhou, Guangdong, China.
Hou L
No affiliation info available
Shi H
No affiliation info available
Zhong X
No affiliation info available
Zhang Y
No affiliation info available
Zheng D
No affiliation info available
Tan Y
No affiliation info available
Hu G
No affiliation info available
Mu N
No affiliation info available
Chan J
No affiliation info available
Chen X
No affiliation info available
Fang Y
No affiliation info available
Wu F
No affiliation info available
He H
No affiliation info available
Ning Y
No affiliation info available

MeSH

AdultAgedAged, 80 and overAlzheimer DiseaseAmyloid beta-PeptidesBiomarkersCerebrospinal FluidDiagnosis, DifferentialFemaleHumansLewy Body DiseaseMaleMiddle AgedNeurocalcinPeptide FragmentsPlaque, AmyloidROC CurveSensitivity and Specificityalpha-Synucleintau Proteins

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23800322

Citation

Luo, Xinni, et al. "CSF Levels of the Neuronal Injury Biomarker Visinin-like Protein-1 in Alzheimer's Disease and Dementia With Lewy Bodies." Journal of Neurochemistry, vol. 127, no. 5, 2013, pp. 681-90.
Luo X, Hou L, Shi H, et al. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies. J Neurochem. 2013;127(5):681-90.
Luo, X., Hou, L., Shi, H., Zhong, X., Zhang, Y., Zheng, D., Tan, Y., Hu, G., Mu, N., Chan, J., Chen, X., Fang, Y., Wu, F., He, H., & Ning, Y. (2013). CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies. Journal of Neurochemistry, 127(5), 681-90. https://doi.org/10.1111/jnc.12331
Luo X, et al. CSF Levels of the Neuronal Injury Biomarker Visinin-like Protein-1 in Alzheimer's Disease and Dementia With Lewy Bodies. J Neurochem. 2013;127(5):681-90. PubMed PMID: 23800322.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies. AU - Luo,Xinni, AU - Hou,Le, AU - Shi,Haishan, AU - Zhong,Xiaomei, AU - Zhang,Yufeng, AU - Zheng,Dong, AU - Tan,Yan, AU - Hu,Guoyan, AU - Mu,Nan, AU - Chan,Jianping, AU - Chen,Xinru, AU - Fang,Yaxiu, AU - Wu,Fengchun, AU - He,Hongbo, AU - Ning,Yuping, Y1 - 2013/06/26/ PY - 2013/03/19/received PY - 2013/05/24/revised PY - 2013/06/04/accepted PY - 2013/6/27/entrez PY - 2013/6/27/pubmed PY - 2014/5/13/medline KW - Alzheimer's disease KW - VILIP-1 KW - biomarkers KW - cerebrospinal fluid KW - dementia with Lewy bodies KW - α-synuclein SP - 681 EP - 90 JF - Journal of neurochemistry JO - J Neurochem VL - 127 IS - 5 N2 - The overlapping clinical features of Alzheimer's disease (AD) and Dementia with Lewy bodies (DLB) make differentiation difficult in the clinical environment. Evaluating the CSF levels of biomarkers in AD and DLB patients could facilitate clinical diagnosis. CSF Visinin-like protein-1 (VILIP-1), a calcium-mediated neuronal injury biomarker, has been described as a novel biomarker for AD. The aim of this study was to investigate the diagnostic utility of CSF VILIP-1 and VILIP-1/Aβ1-42 ratio to distinguish AD from DLB. Levels of CSF VILIP-1, t-tau, p-tau181P , Aβ1-42 , and α-synuclein were measured in 61 AD patients, 32 DLB patients, and 40 normal controls using commercial ELISA kits. The results showed that the CSF VILIP-1 level had significantly increased in AD patients compared with both normal controls and DLB patients. The CSF VILIP-1 and VILIP-1/Aβ1-42 levels had enough diagnostic accuracy to allow the detection and differential diagnosis of AD. Additionally, CSF VILIP-1 levels were positively correlated with t-tau and p-tau181P within each group and with α-synuclein in the AD and control groups. We conclude that CSF VILIP-1 could be a diagnostic marker for AD, differentiating it from DLB. The analysis of biomarkers, representing different neuropathologies, is an important approach reflecting the heterogeneous features of AD and DLB. Neuronal Ca(2+) -sensor protein VILIP-1 has been implicated in the calcium-mediated neuronal injury and pathological change of AD. The CSF VILIP-1 and VILIP-1/Aβ1-42 levels had enough diagnostic accuracy to allow the detection and differential diagnosis of AD. CSF VILIP-1 is a useful biomarker for AD. Evaluating the CSF levels of VILIP-1 in AD and DLB patients could facilitate clinical diagnosis. SN - 1471-4159 UR - https://www.unboundmedicine.com/medline/citation/23800322/CSF_levels_of_the_neuronal_injury_biomarker_visinin_like_protein_1_in_Alzheimer's_disease_and_dementia_with_Lewy_bodies_ DB - PRIME DP - Unbound Medicine ER -